Scarica l'app Stockscreener
60.27
1.58%
0.94
Dopo l'orario di chiusura:
60.27
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
BioMarin Partners with n-Lorem to Develop Therapy for ReNU Syndrome - Intellectia AI
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
BioMarin partners with n-Lorem to develop ReNU syndrome treatment - Investing.com
BioMarin partners with n-Lorem to develop ReNU syndrome treatment By Investing.com - Investing.com Canada
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome - PR Newswire
TradingKey - TradingKey
Biomarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
BioMarin Pharmaceutical Inc (BMRN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioMarin Pharmaceutical (NASDAQ:BMRN) Presents a High-Quality Breakout Setup with Strong Technical Ratings - ChartMill
BioMarin Pharmaceutical Inc (BMRN) Institutional Confidence - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biomarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Biomarin Pharmaceutical Inc. (BMRN) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
BMRN|BioMarin Pharmaceutical Inc|Price:59.350|Chg%:+0.480 - TradingKey
BioMarin Pharmaceutical Inc (BMRN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Layoff Tracker: CLINUVEL will cut up to 20% of staff, relocate HQ to New York - BioSpace
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset - Seeking Alpha
BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops - Ad-hoc-news.de
Biotech Advances VOXZOGO Toward Landmark US FDA Approval - Streetwise Reports
BMRN5187965 Bond Profile — Key Metrics - TradingView
BioMarin Pharmaceutical Inc. (BMRN) Investor Outlook: A 47.61% Upside Opportunity In Biotech - DirectorsTalk Interviews
US9061GAK7 Bond Profile — Key Metrics - TradingView
2 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Yahoo Finance
Trading Systems Reacting to (BMRN) Volatility - Stock Traders Daily
BioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasia - Sahm
BMRN Maintained by Citigroup -- Price Target Raised to $76.00 - GuruFocus
Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharma - BioSpace
BMRN6299744 Bond Risk Profile - TradingView
H.C. Wainwright reiterates BioMarin stock rating at Neutral By Investing.com - Investing.com South Africa
BMRN6299744 Bond Profile — Key Metrics - TradingView
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo - Yahoo Finance
H.C. Wainwright reiterates BioMarin stock rating at Neutral - Investing.com
Amicus Therapeutics Reports 2025 Financial Results, Merger With BioMarin, and Key Pipeline Updates - Minichart
BioMarin SNDA seeking full Voxzogo approval accepted by FDA - MSN
BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation - Yahoo Finance
BioMarin (BMRN) details Amicus 2025 results and $14.50-per-share merger terms - Stock Titan
FDA accepts BioMarin application for full VOXZOGO approval - Investing.com UK
BioMarin seeks full approval for VOXZOGO - grafa.com
FDA accepts BioMarin application for full VOXZOGO approval By Investing.com - Investing.com Australia
BioMarin Seeks Full Approval for VOXZOGO in Achondroplasia - Intellectia AI
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia - PR Newswire
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit - AOL.com
Young people with PKU take the mic in BioMarin podcast series - Fierce Pharma
Is BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions? - Sahm
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth - TradingView
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead - TradingView
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):